Systemic sequential therapy of psoriasis: A new paradigm for improved therapeutic results

被引:90
作者
Koo, J [1 ]
机构
[1] Univ Calif San Francisco, Psoriasis & Skin Treatment Ctr, San Francisco, CA 94118 USA
关键词
D O I
10.1016/S0190-9622(99)70363-4
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Sequential therapy is a treatment strategy involving the use of specific therapeutic agents in a deliberate sequence to optimize the therapeutic outcome. The rationale for this strategy in psoriasis is that it is a chronic disease requiring long-term maintenance therapy as well as quick relief of symptoms and that some therapies available for psoriasis are better suited for rapid clearance while others are more appropriate for long-term maintenance. Sequential therapy involves 3 main steps: (1) the clearing, or "quick-fix" phase; (2) the transitional phase; and (3) the maintenance phase. In the example of sequential systemic therapy described in this article, an acute exacerbation of psoriasis is brought under control promptly with the use of cyclosporine at maximum dermatologic dose (5 mg/kg daily). After 1 month, the transitional phase Is initiated with the gradual introduction of acitretin as a maintenance agent. Once the maximum tolerated dose of acitretin has been established, cyclosporine is gradually tapered and acitretin is continued for longterm maintenance with phototherapy (UVB or PUVA) added for improved control if needed. The author proposes sequential therapy with cyclosporine and acitretin as a viable option for patients with psoriasis who require systemic therapy and desire an alternative to methotrexate.
引用
收藏
页码:S25 / S28
页数:4
相关论文
共 21 条
[1]  
BAVINCK JN, 1995, J CLIN ONCOL, P1933
[2]   Methotrexate for psoriasis [J].
Boffa, MJ ;
Chalmers, RJG .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1996, 21 (06) :399-408
[3]   CYCLOSPORINE FOR PLAQUE-TYPE PSORIASIS - RESULTS OF A MULTIDOSE, DOUBLE-BLIND TRIAL [J].
ELLIS, CN ;
FRADIN, MS ;
MESSANA, JM ;
BROWN, MD ;
SIEGEL, MT ;
HARTLEY, AH ;
ROCHER, LL ;
WHEELER, S ;
HAMILTON, TA ;
PARISH, TG ;
ELLISMADU, M ;
DUELL, E ;
ANNESLEY, TM ;
COOPER, KD ;
VOORHEES, JJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (05) :277-284
[4]  
ELLIS CN, 1993, SYSTEMIC RETINOID TH, P95
[5]  
Georgouras K E, 1997, Australas J Dermatol, V38, P171, DOI 10.1111/j.1440-0960.1997.tb01690.x
[6]   VERTEBRAL ABNORMALITIES ASSOCIATED WITH SYNTHETIC RETINOID USE [J].
GERBER, LH ;
HELFGOTT, RK ;
GROSS, EG ;
HICKS, JE ;
ELLENBERG, SS ;
PECK, GL .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1984, 10 (05) :817-823
[7]   Long-term safety of cyclosporine in the treatment of psoriasis [J].
Grossman, RM ;
Chevret, S ;
AbiRached, J ;
Blanchet, F ;
Dubertret, L .
ARCHIVES OF DERMATOLOGY, 1996, 132 (06) :623-629
[8]   A RETROSPECTIVE STUDY OF BONE CHANGES IN ADULTS TREATED WITH ETRETINATE [J].
HALKIERSORENSEN, L ;
ANDRESEN, J .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1989, 20 (01) :83-87
[9]  
Koo J, 1997, Adv Dermatol, V12, P47
[10]   Cyclosporine consensus conference: With emphasis on the treatment of psoriasis [J].
Lebwohl, M ;
Ellis, C ;
Gottlieb, A ;
Koo, J ;
Krueger, G ;
Linden, K ;
Shupack, J ;
Weinstein, G .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1998, 39 (03) :464-475